Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890888 | 1.00 | ABCB1 (0.41) | ABCB1FFAR2RIPK1GPR119MCL1 | |
| SCHEMBL2890883 | 1.00 | ABCB1 (0.41) | ABCB1FFAR2RIPK1GPR119MCL1 | |
| SCHEMBL10209962 | 0.89 | ABCB1 (0.44) | ABCB1FFAR2RIPK1GPR119USP30 | |
| SCHEMBL28528400 | 0.88 | GPR119 (0.41) | ABCB1GPR119 | |
| SCHEMBL21094096 | 0.87 | FFAR2 (0.44) | ABCB1FFAR2RIPK1UCHL1USP30 | |
| SCHEMBL21094369 | 0.87 | RIPK1 (0.45) | FFAR2RIPK1GPR119 | |
| SCHEMBL8870747 | 0.86 | ABCB1 (0.41) | ABCB1FFAR2RIPK1GPR119UCHL1 | |
| SCHEMBL8870762 | 0.86 | ABCB1 (0.41) | ABCB1FFAR2RIPK1GPR119UCHL1 | |
| SCHEMBL20835408 | 0.85 | FFAR2 (0.45) | FFAR2RIPK1MCL1BCL2 | |
| SCHEMBL21094088 | 0.84 | FFAR2 (0.42) | FFAR2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820680-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1725102-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20080009490-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| EP-1725102-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005092099-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009490-A1 | Hiv Integrase Inhibitors | TYMS, UNG, TYMP | ABCB1 233/4885FFAR2 4535/4885RIPK1 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.